Fifth Third Bancorp’s Avalo Therapeutics AVTX Stock Holding History

Fifth Third Bancorp’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1	Closed	-$34	–	2501
2023 Q3	$34	Buy	+1	New	+$45	﹤0.01%	2573

Other funds holding AVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fifth Third Bancorp's AVTX Position: Q4 2023 in Review

Fifth Third Bancorp sold out of Avalo Therapeutics (AVTX) in Q4 2023, closing a stake of 1 share — an estimated $34 sold.

Fifth Third Bancorp first reported a position in AVTX in Q3 2023 and held it in 1 quarter. The position peaked at $34 in Q3 2023. 12 funds tracked by Wall St. Rank hold AVTX as of Q4 2023.

Fifth Third Bancorp reported no remaining Avalo Therapeutics position as of Q4 2023 after selling out during the quarter.
Fifth Third Bancorp sold 1 Avalo Therapeutics share in Q4 2023, an estimated $34.
Fifth Third Bancorp first reported a position in Avalo Therapeutics in Q3 2023 and held it in 1 quarter.
Fifth Third Bancorp's Avalo Therapeutics position peaked at $34 in Q3 2023.
12 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2023.

Based on Fifth Third Bancorp's 13F filing for Q4 2023, filed 19 Jan 2024.